{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:23:25Z","timestamp":1763036605316},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00104-011-2073-0","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T17:15:17Z","timestamp":1309972517000},"page":"612-617","source":"Crossref","is-referenced-by-count":2,"title":["Metastasierte neuroendokrine Neoplasien","Metastatic neuroendocrine neoplasms"],"prefix":"10.1007","volume":"82","author":[{"given":"M.","family":"Pavel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"2073_CR1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","volume":"59","author":"Bajetta","year":"2007","unstructured":"Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637\u2013642","journal-title":"Cancer Chemother Pharmacol"},{"key":"2073_CR2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"Bushnell","year":"2010","unstructured":"Bushnell DL Jr, O\u2019Dorisio TM, O\u2019Dorisio MS et al (2010) 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652\u20131659","journal-title":"J Clin Oncol"},{"key":"2073_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","volume":"87","author":"Eriksson","year":"2008","unstructured":"Eriksson B, Kl\u00f6ppel G, Krenning E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors \u2013 well-differentiated jejunal-ileal tumor\/carcinoma. Neuroendocrinology 87:8\u201319","journal-title":"Neuroendocrinology"},{"key":"2073_CR4","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","unstructured":"Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors \u2013 the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689\u20132696","journal-title":"J Clin Oncol"},{"key":"2073_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000117575","volume":"88","author":"Fjallskog","year":"2008","unstructured":"Fjallskog ML, Janson ET, Falkmer UG et al (2008) Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 88:53\u201358","journal-title":"Neuroendocrinology"},{"key":"2073_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","volume":"32","author":"Janson","year":"1993","unstructured":"Janson ET, Oberg K (1993) Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225\u2013229","journal-title":"Acta Oncol"},{"key":"2073_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000098009","volume":"84","author":"Jensen","year":"2006","unstructured":"Jensen RT, Niederle B, Mitry E et al; Frascati Consensus Conference;European Neuroendocrine Tumor Society (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84:173\u2013182","journal-title":"Neuroendocrinology"},{"key":"2073_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000287255","volume":"91","author":"Kos-Kud\u0142a","year":"2010","unstructured":"Kos-Kud\u0142a B, O\u2019Toole D, Falconi M et al (2010) ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91:341\u2013350","journal-title":"Neuroendocrinology"},{"key":"2073_CR9","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"Kouvaraki","year":"2004","unstructured":"Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762\u20134771","journal-title":"J Clin Oncol"},{"key":"2073_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","volume":"360","author":"Kulke","year":"2009","unstructured":"Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360(2):195\u2013197","journal-title":"N Engl J Med"},{"key":"2073_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","volume":"31","author":"Modlin","year":"2010","unstructured":"Modlin IM, Pavel ME, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 31:169\u2013188","journal-title":"Aliment Pharmacol Ther"},{"key":"2073_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"Moertel","year":"1992","unstructured":"Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519\u2013523","journal-title":"N Engl J Med"},{"key":"2073_CR13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000098013","volume":"84","author":"Nilsson","year":"2006","unstructured":"Nilsson O, Cutsem E, Delle Fave G Van et al; Frascati Consensus Conference; European Neuroendocrine Tumor Society (2006) Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84:212\u2013215","journal-title":"Neuroendocrinology"},{"key":"2073_CR14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"\u00d6berg","year":"2004","unstructured":"\u00d6berg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966\u2013973","journal-title":"Ann Oncol"},{"key":"2073_CR15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","volume":"62","author":"\u00d6berg","year":"2000","unstructured":"\u00d6berg K (2000) Interferon in the management of neuroendocrine GEP tumors. Digestion 62 (Suppl 1):92\u201397","journal-title":"Digestion"},{"key":"2073_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","volume":"26","author":"Pavel","year":"2006","unstructured":"Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFNalpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8\u201313","journal-title":"J Interferon Cytokine Res"},{"key":"2073_CR17","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdp580","volume":"21","author":"Pavel","year":"2010","unstructured":"Pavel M, Hainsworth JD, Baudin E et al (2010) A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21 (Suppl 8):viii1\u2013viii12, LBA8","journal-title":"Ann Oncol"},{"key":"2073_CR18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000242109","volume":"90","author":"Ploeckinger","year":"2009","unstructured":"Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90(4):349\u2013363","journal-title":"Neuroendocrinology"},{"key":"2073_CR19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul J-L et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501\u2013513","journal-title":"N Engl J Med"},{"key":"2073_CR20","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"28","author":"Rinke","year":"2009","unstructured":"Rinke A, Muller H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 28:4656\u20134663","journal-title":"J Clin Oncol"},{"key":"2073_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000051859","volume":"62","author":"Rougier","year":"2000","unstructured":"Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62 (Suppl 1):73\u201378","journal-title":"Digestion"},{"key":"2073_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","volume":"94","author":"Shojamanesh","year":"2002","unstructured":"Shojamanesh H, Gibril F, Louie A et al (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94(2):331\u2013343","journal-title":"Cancer"},{"key":"2073_CR23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"Strosberg","year":"2011","unstructured":"Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268\u2013275","journal-title":"Cancer"},{"key":"2073_CR24","doi-asserted-by":"crossref","unstructured":"Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, doi 10.1002\/cncr.26124","DOI":"10.1002\/cncr.26124"},{"key":"2073_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-011-2073-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00104-011-2073-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-011-2073-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T14:26:27Z","timestamp":1712586387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00104-011-2073-0"}},"subtitle":["Nichtoperative Therapiekonzepte","Non-surgical treatment strategies"],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s00104-011-2073-0","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}